AVEO Pharmaceuticals, Inc. (AVEO 8.50, +0.02, +0.24%) , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the appointment of Michael P. Bailey to the newly created role of chief commercial officer, as well as the addition of Donna M. Radzik, Ph.D., in the newly created role of vice president, technical operations. Both of these positions will report to Elan Ezickson, executive vice president and chief business officer of AVEO.
"We are very pleased to welcome Michael and Donna to our organization," said Tuan Ha-Ngoc, president and chief executive officer of AVEO. "These strategic appointments and additions to our team come as we prepare for the upcoming regulatory and commercial planning activities associated with our triple VEGF receptor inhibitor, tivozanib, now that we have completed enrollment in our global Phase 3 clinical trial, TIVO-1, in patients with renal cell carcinoma."
"Michael's experiences in building commercial organizations and leading the global launch of Erbitux(R) across multiple oncology indications, as well as Donna's experience with CMC and supply chain matters, will be important as AVEO prepares for commercialization of tivozanib in renal cell cancer and other future potential indications," said Mr. Ezickson. "These appointments represent continued strategic growth for AVEO and will provide us with the added depth and breadth we believe are appropriate for a rapidly advancing oncology company."
Mr. Bailey brings more than 18 years of experience in the pharmaceutical industry to AVEO and joins the company from Synta Pharmaceuticals, where he served as senior vice president, business development and chief commercial officer since 2008. Prior to joining Synta, Mr. Bailey led ImClone's Worldwide Commercial Organization, where he was responsible for commercial aspects for the planning and launch of Erbitux across multiple indications. In addition, Mr. Bailey was a key member of the strategic leadership committees for ImClone and its North American and worldwide partnerships. Prior to his role at ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc. and was a key member of their global commercial partnership teams. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from the University of Notre Dame Graduate School of Business.
Dr. Radzik has more than 25 years of experience in the biopharmaceutical industry where she has contributed to the development, approval and commercial technical support of both small and large molecule therapies. Prior to joining AVEO, Dr. Radzik most recently served as vice president, technical operations at Sanofi Pasteur Biologics (formerly Acambis) where she was responsible for bulk and drug product production of live viral vaccines. Prior to this role, Dr. Radzik served as senior vice president of U.S. technical operations for UCB, where she was a site director and accountable for the supply chain of numerous products. Prior to joining UCB by acquisition, she held various senior positions at Celltech and Celltech's predecessor, Medeva Inc., including head of technical operations and development and global quality assurance. She has also held leadership roles at Hoechst-Roussel, Marion Merrell Dow and Lederle Laboratories/Medical Research Division of American Cyanamid. Dr. Radzik received a B.S. in chemistry from Grand Valley State University and a Ph.D. in analytical chemistry from Purdue University.
"We are very pleased to welcome Michael and Donna to our organization," said Tuan Ha-Ngoc, president and chief executive officer of AVEO. "These strategic appointments and additions to our team come as we prepare for the upcoming regulatory and commercial planning activities associated with our triple VEGF receptor inhibitor, tivozanib, now that we have completed enrollment in our global Phase 3 clinical trial, TIVO-1, in patients with renal cell carcinoma."
"Michael's experiences in building commercial organizations and leading the global launch of Erbitux(R) across multiple oncology indications, as well as Donna's experience with CMC and supply chain matters, will be important as AVEO prepares for commercialization of tivozanib in renal cell cancer and other future potential indications," said Mr. Ezickson. "These appointments represent continued strategic growth for AVEO and will provide us with the added depth and breadth we believe are appropriate for a rapidly advancing oncology company."
Mr. Bailey brings more than 18 years of experience in the pharmaceutical industry to AVEO and joins the company from Synta Pharmaceuticals, where he served as senior vice president, business development and chief commercial officer since 2008. Prior to joining Synta, Mr. Bailey led ImClone's Worldwide Commercial Organization, where he was responsible for commercial aspects for the planning and launch of Erbitux across multiple indications. In addition, Mr. Bailey was a key member of the strategic leadership committees for ImClone and its North American and worldwide partnerships. Prior to his role at ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc. and was a key member of their global commercial partnership teams. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from the University of Notre Dame Graduate School of Business.
Dr. Radzik has more than 25 years of experience in the biopharmaceutical industry where she has contributed to the development, approval and commercial technical support of both small and large molecule therapies. Prior to joining AVEO, Dr. Radzik most recently served as vice president, technical operations at Sanofi Pasteur Biologics (formerly Acambis) where she was responsible for bulk and drug product production of live viral vaccines. Prior to this role, Dr. Radzik served as senior vice president of U.S. technical operations for UCB, where she was a site director and accountable for the supply chain of numerous products. Prior to joining UCB by acquisition, she held various senior positions at Celltech and Celltech's predecessor, Medeva Inc., including head of technical operations and development and global quality assurance. She has also held leadership roles at Hoechst-Roussel, Marion Merrell Dow and Lederle Laboratories/Medical Research Division of American Cyanamid. Dr. Radzik received a B.S. in chemistry from Grand Valley State University and a Ph.D. in analytical chemistry from Purdue University.
No comments:
Post a Comment